PANCRAZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.070
EU - Europa 3.145
AS - Asia 518
OC - Oceania 25
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.771
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.065
PL - Polonia 1.364
RU - Federazione Russa 723
IT - Italia 236
IE - Irlanda 232
SE - Svezia 222
CN - Cina 149
SG - Singapore 146
DE - Germania 99
HK - Hong Kong 88
UA - Ucraina 65
FI - Finlandia 63
IN - India 47
CH - Svizzera 44
FR - Francia 43
GB - Regno Unito 28
JO - Giordania 25
AU - Australia 24
VN - Vietnam 23
ID - Indonesia 12
TR - Turchia 11
CI - Costa d'Avorio 10
ES - Italia 7
KR - Corea 6
BE - Belgio 5
BG - Bulgaria 5
AE - Emirati Arabi Uniti 4
CA - Canada 4
NL - Olanda 4
AT - Austria 2
JP - Giappone 2
SC - Seychelles 2
TW - Taiwan 2
BD - Bangladesh 1
EU - Europa 1
LT - Lituania 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 7.771
Salva come PNG Salva come JPEG
Città #
Warsaw 1.364
Santa Clara 964
Fairfield 534
Chandler 279
Ashburn 252
Woodbridge 232
Dublin 230
Seattle 217
Cambridge 193
Houston 189
Wilmington 165
Singapore 112
Jacksonville 111
Ann Arbor 86
Altamura 73
Beijing 67
Lawrence 67
Princeton 63
Hong Kong 45
Bern 44
Buffalo 42
Boston 39
Mumbai 38
Bremen 35
Boardman 33
Shanghai 30
Medford 25
San Diego 24
Florence 23
Melbourne 23
New York 23
Los Angeles 18
Dearborn 16
Dong Ket 16
Helsinki 13
Jakarta 12
Kent 12
Montepulciano 12
Norwalk 11
Phoenix 11
Abidjan 10
Falls Church 8
Pune 8
Redwood City 8
Salerno 8
Barcelona 7
Izmir 7
Moscow 7
Andover 6
Auburn Hills 6
Fuzhou 6
Hillsboro 6
Milan 6
Pian di Scò 6
Seoul 6
Cantagallo 5
Sofia 5
Yubileyny 5
Abu Dhabi 4
Brussels 4
Frankfurt Am Main 4
London 4
Munich 4
Nanjing 4
Old Bridge 4
Paris 4
Romainville 4
West Jordan 4
Newark 3
Pisa 3
Rome 3
Zhengzhou 3
Arezzo 2
Burghausen 2
Corsico 2
Costa Mesa 2
Farra di Soligo 2
Hangzhou 2
Hebei 2
Kaohsiung 2
Nanchang 2
Napoli 2
Nürnberg 2
Pavia 2
Red Deer 2
Santa Maria la Fossa 2
Sesto Fiorentino 2
Shaoxing 2
Siena 2
Turin 2
Verona 2
Vienna 2
Villa Minozzo 2
Washington 2
Wuhan 2
Acton 1
Arnsberg 1
Auckland 1
Augusta 1
Azzano Decimo 1
Totale 5.966
Salva come PNG Salva come JPEG
Nome #
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 293
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 287
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 287
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 285
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 280
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 277
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 275
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 265
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 252
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 248
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 192
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 182
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 167
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 158
Mutations and prognosis in primary myelofibrosis. 153
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 152
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 151
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 147
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 144
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 141
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 140
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 135
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 134
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 133
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 130
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS 129
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 127
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 127
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. 127
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 124
WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential 121
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 121
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 118
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 118
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 118
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders–A consensus project of the Italian Society of Hematology 114
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. 111
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. 107
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 105
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 103
Variegation of the phenotype induced by the GATA-1low mutation in mice of different genetic backgrounds. 100
PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. 99
A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis 97
CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. 96
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 95
ANALISI MUTAZIONALI DELLE MALATTIE MIELOPROLIFERTAIVE CRONICHE 86
MPL mutational analysis in chronic myeloproliferative disorders 82
Analisi mutazionale delle malattie mieloproliferative croniche 76
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 74
Internal tandem duplication of FLT3 gene (FLT3/TID) predicts a poor post-remission outcome in adult patients witha cute non-promyelocytic leukemia 71
Primary myelofibrosis with or without mutant MPL: comparison ofsurvival and clinical features involving 603 patients. 62
ANALYSIS OF ASXL1 MUTATIONS IN 215 PATIENTS WITH MYELOFIBROSIS : IMPACT ON DISEASE PHENOTYPE AND PROGNOSIS 54
LNK MUTATIONS IN JAK2 NEGATIVE ERYTHROCYTOSIS 48
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 38
Totale 7.856
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.854
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.854
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020782 0 0 0 0 0 0 178 192 142 105 145 20
2020/2021805 74 67 40 121 36 70 42 75 64 113 48 55
2021/2022415 22 43 34 16 15 12 17 35 14 9 88 110
2022/20231.170 98 218 67 115 87 193 136 69 105 3 31 48
2023/2024369 13 45 56 17 39 74 11 59 3 14 25 13
2024/20252.133 76 271 196 383 775 432 0 0 0 0 0 0
Totale 7.856